Stringent Product Validation

The first Chinese precision medicine company
that published a validation study of
NGS-based test with broad gene panel.

This is the world’s first paper on validation of broad-panel NGS assay by assessing TMB and MSI as biomarkers both in targeted and immunotherapies.
OrigiMed’s whole-process quality control follows the highest industry standards and all series of products are systematically validated.
To ensure the precise and accurate testing result accessible to every patient; to powerfully underpin physicians’ clinical decisions.

Learn more >

The research was published in the world’s authoritative oncology journal, JCO Precision Oncology, an official publication of ASCO.
This head-to-head comparative study is the first to compare a Chinese sequencing product with an FDA-approved broad panel test for the same study samples. According to the result, OrigiMed’s broad panel test showed a high degree of concordance with FDA-approved F1CD from Foundation Medicine in several studied genes and variations.